85691-74-3

Usage

Uses

Used in Pharmaceutical Industry:
Pirmagrel is used as an antithrombotic agent for the treatment of thrombosis and ischemic heart disorders. Its mechanism of action involves inhibiting thromboxane synthetase, thereby reducing the production of thromboxane A2, which plays a crucial role in platelet aggregation and vasoconstriction. This inhibition helps in preventing blood clot formation and improving blood flow, making it a beneficial treatment option for patients with these conditions.

InChI:InChI=1/C13H16N2O2/c16-13(17)8-3-1-2-5-11-6-4-7-12-9-14-10-15(11)12/h4,6-7,9-10H,1-3,5,8H2,(H,16,17)

Upstream product

• 85691-87-8 5-(6-hydroxyhexyl)imidazo<1,5-a>pyridine 
• 85703-84-0 5-(lithiomethyl)imidazo[1,5-a]pyridine 
• 2067-33-6 5-bromopentanoic acid 
• 6558-64-1 5-methylimidazo<1,5-a>pyridine 
• 64-17-5 ethanol 
• 85691-73-2 5-(5-ethoxycarbonylpentyl)-imidazo[1,5-a]pyridine 
• 85691-40-3 5-bromo-1,1,1-triethoxypentane 

Relevant academic research and scientific papers

Imidazo[1,5-a]pyridines: A new class of thromboxane A2 synthetase inhibitors

The synthesis and structure-activity profile of a new class of potent and highly specific thromboxane A2 synthetase inhibitors is described. The most potent member of this series in vitro is determined to be imidazo[1,5-a]pyridine-5-hexanoic acid.

Certain imidazo(1,5-a)pyridine derivatives and their use as thromboxane synthetase inhibitors

Disclosed are compounds of the formula I STR1 or a 5,6,7,8-tetrahydro derivative thereof, wherein R1 is hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy, or aryl-lower alkoxy in which aryl represents phenyl or phenyl substituted by lower alkoxy, lower alkyl, halogen or trifluoromethyl; R2 represents hydrogen, halogen, or lower alkyl; C represents carboxy, lower alkoxycarbonyl, unsubstituted or mono- or di-(lower alkyl) substituted carbamoyl, cyano, formyl, hydroxymethyl, 5-tetrazolyl, dihydro-2-oxazolyl, dihydro-2-oxazolyl substituted by lower alkyl, or hydroxycarbamoyl; and (a) A represents ethenylene or ethenylene substituted by lower alkyl; B is straight chain or branched alkylene of 1 to 12 carbon atoms, alkynylene or alkenylene of 2 to 12 carbon atoms, phenylene-lower alkylene, phenylene-lower alkenylene, phenylene, or phenylene-(thio or oxy)-lower alkylene; or (b) A represents a direct bond; B represents lower alkylenephenylene, phenylene lower alkylene, phenylene, lower alkylene-(thio or oxy)-lower alkylene, lower alkylene-(thio or oxy)-phenylene, phenylene-(thio or oxy)-lower alkylene, phenylene-lower alkenylene, lower alkylenephenylene-lower alkenylene, or straight chain or branched alkadienylene of 5 to 12 carbon atoms; or a pharmaceutically acceptable salt thereof; and methods of synthesis thereof. Said compounds are useful as selective thromboxane synthetase inhibitors for the treatment of diseases such as cerebral ischaemia, shock, thrombosis and ischaemic heart disease.

Substituted imidazo[1,5-A]pyridines

Disclosed are e.g. novel 5-(carboxyalkyl)imidazo[1,5-a]pyridines, their derivatives and methods of synthesis. Said compounds are useful as selective thromboxane synthetase inhibitors for the treatment of diseases such as cerebral ischaemia, shock, thrombo

Certain imidazo (1,5-A) pyridine aliphatic carboxylic acid derivatives and their use as selective thromboxane inhibitors

Disclosed are e.g. 5-(tetrazolylalkyl, hydroxycarbamoylalkyl)imidazo[1,5-a]-pyridines, and methods of synthesis. Said compounds are useful as selective thromboxane synthetase inhibitors for the treatment of diseases such as cerebral ischaemia, shock, thro